{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:23:47Z","timestamp":1787563427410,"version":"build-2736575974"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Trial evidence indicates that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of cardiovascular (CV) events in patients with diabetes and myocardial infarction (MI). We aimed to expand this observation to routine care settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Prospective observational study including all patients with diabetes surviving an MI and registered in the nationwide SWEDEHEART registry during 2010\u201317. Multivariable Cox regression analyses were used to estimate the association between GLP-1 RAs use and the study outcome, which was a composite of stroke, heart failure, Re-infarction, or CV death. Covariates included demographics, comorbidities, presentation at admission, and use of secondary CV prevention therapies. In total, 17 868 patients with diabetes were discharged alive after a first event of MI. Their median age was 71\u2009years, 36% were women and their median estimated glomerular filtration rate was 75\u2009mL\/min\/1.73m2. Of those, 365 (2%) were using GLP-1 RAs. During median 3\u2009years of follow-up, 7005 patients experienced the primary composite outcome. Compared with standard of diabetes care, use of GLP-1 RAs was associated with a lower event risk [adjusted hazard ratio (HR) 0.72; 95% confidence interval (CI): 0.56\u20130.92], mainly attributed to a lower rate of re-infarction and stroke. Results were similar after propensity score matching or when compared with users of sulfonylurea. There was no suggestion of heterogeneity across subgroups of age, sex, chronic kidney disease, and STEMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1 RAs use, compared with standard of diabetes care, was associated with lower risk for major CV events in healthcare-managed survivors of an MI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaa004","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T15:10:14Z","timestamp":1579792214000},"page":"104-111","source":"Crossref","is-referenced-by-count":40,"title":["Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9578-0171","authenticated-orcid":false,"given":"Marco","family":"Trevisan","sequence":"first","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels v\u00e4g 12A, 171 77 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard L","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Szummer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Karolinska University Hospital, Solna, Sweden"},{"name":"Department of Medicine, Karolinska Institutet, Huddinge, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Norhammar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Solna, Sweden"},{"name":"Capio Saint G\u00f6rans hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9614-0486","authenticated-orcid":false,"given":"Pia","family":"Lundman","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Department of Medicine, W\u00fcrzburg University Clinic, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5226-6685","authenticated-orcid":false,"given":"Arvid","family":"Sj\u00f6lander","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels v\u00e4g 12A, 171 77 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-379X","authenticated-orcid":false,"given":"Tomas","family":"Jernberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-2024","authenticated-orcid":false,"given":"Juan Jesus","family":"Carrero","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels v\u00e4g 12A, 171 77 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"2021031509395363300_pvaa004-B1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/cvr\/cvz197","article-title":"Statistics on mortality following acute myocardial infarction in 842,897 Europeans","volume":"116","author":"Alabas","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2021031509395363300_pvaa004-B2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.298.7.765","article-title":"Diabetes and mortality following acute coronary syndromes","volume":"298","author":"Donahoe","year":"2007","journal-title":"JAMA"},{"key":"2021031509395363300_pvaa004-B3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1136\/hrt.2006.097956","article-title":"Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission","volume":"93","author":"Norhammar","year":"2006","journal-title":"Heart"},{"key":"2021031509395363300_pvaa004-B4","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S0735-1097(96)00397-X","article-title":"Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience","volume":"28","author":"Woodfield","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"2021031509395363300_pvaa004-B5","doi-asserted-by":"crossref","first-page":"e002328","DOI":"10.1161\/CIRCINTERVENTIONS.114.002328","article-title":"High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish coronary angiography and angioplasty registry","volume":"8","author":"Ritsinger","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"2021031509395363300_pvaa004-B6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2021031509395363300_pvaa004-B7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"2021031509395363300_pvaa004-B8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2021031509395363300_pvaa004-B9","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2021031509395363300_pvaa004-B10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"2021031509395363300_pvaa004-B11","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2021031509395363300_pvaa004-B12","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"2021031509395363300_pvaa004-B13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2021031509395363300_pvaa004-B14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"2021031509395363300_pvaa004-B15","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/hrt.2010.198804","article-title":"The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART)","volume":"96","author":"Jernberg","year":"2010","journal-title":"Heart"},{"key":"2021031509395363300_pvaa004-B16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2021031509395363300_pvaa004-B17","volume-title":"Modern Epidemiology.","author":"Rothman","edition":"3rd ed."},{"key":"2021031509395363300_pvaa004-B18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10654-016-0157-3","article-title":"Regression standardization with the R package stdReg","volume":"31","author":"Sj\u00f6lander","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"2021031509395363300_pvaa004-B19","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfy283","article-title":"Merits and caveats of propensity scores to adjust for confounding","volume":"34","author":"Fu","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2021031509395363300_pvaa004-B20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(18)30320-6","article-title":"Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden","volume":"7","author":"Svanstr\u00f6m","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2021031509395363300_pvaa004-B21","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/dom.12665","article-title":"Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study","volume":"18","author":"Patorno","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2021031509395363300_pvaa004-B22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/dme.13898","article-title":"Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis","volume":"36","author":"Hussein","year":"2019","journal-title":"Diabet Med"},{"key":"2021031509395363300_pvaa004-B23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2021031509395363300_pvaa004-B24","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1111\/dom.13847","article-title":"GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials","volume":"21","author":"Giugliano","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2021031509395363300_pvaa004-B25","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2021031509395363300_pvaa004-B26","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.119.041659","article-title":"Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes: insights from the EXSCEL Trial","volume":"140","author":"Fudim","year":"2019","journal-title":"Circulation"},{"key":"2021031509395363300_pvaa004-B27","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","article-title":"Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"138","author":"Mann","year":"2018","journal-title":"Circulation"},{"key":"2021031509395363300_pvaa004-B28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"2021031509395363300_pvaa004-B29","doi-asserted-by":"crossref","first-page":"522-P","DOI":"10.2337\/db18-522-P","article-title":"Renal outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)","volume":"67","author":"Bethel","year":"2018","journal-title":"Diabetes"},{"key":"2021031509395363300_pvaa004-B30","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021031509395363300_pvaa004-B31","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.2337\/dcS13-2018","article-title":"Is glucose control important for prevention of cardiovascular disease in diabetes?","volume":"36","author":"Mannucci","year":"2013","journal-title":"Diabetes Care"},{"key":"2021031509395363300_pvaa004-B32","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1463-1326.2012.01606.x","article-title":"Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis","volume":"14","author":"Liu","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2021031509395363300_pvaa004-B33","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.jacc.2018.07.071","article-title":"The changing landscape of diabetes therapy for cardiovascular risk reduction: JACC state-of-the-art review","volume":"72","author":"Newman","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2021031509395363300_pvaa004-B34","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can","year":"2014","journal-title":"Int J Obes (Lond"},{"key":"2021031509395363300_pvaa004-B35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2021031509395363300_pvaa004-B36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: a critical review of the evidence","volume":"3","author":"Mehta","year":"2017","journal-title":"Obes Sci Pract"},{"key":"2021031509395363300_pvaa004-B37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.atherosclerosis.2017.06.920","article-title":"Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits","volume":"265","author":"Sudo","year":"2017","journal-title":"Atherosclerosis"},{"key":"2021031509395363300_pvaa004-B38","doi-asserted-by":"crossref","first-page":"e97554","DOI":"10.1371\/journal.pone.0097554","article-title":"Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism","volume":"9","author":"Krasner","year":"2014","journal-title":"PLoS One"},{"key":"2021031509395363300_pvaa004-B39","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men","volume":"89","author":"Gutzwiller","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2021031509395363300_pvaa004-B40","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"2021031509395363300_pvaa004-B41","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2021031509395363300_pvaa004-B42","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005536","article-title":"Gastrointestinal-renal axis: role in the regulation of blood pressure","volume":"6","author":"Yang","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2021031509395363300_pvaa004-B43","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/2047487316687860","article-title":"Mortality and extent of coronary artery disease in 2776 patients with type 1 diabetes undergoing coronary angiography: a nationwide study","volume":"24","author":"Ritsinger","year":"2017","journal-title":"Eur J Prev Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaa004\/32529632\/pvaa004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/2\/104\/36599474\/pvaa004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/2\/104\/36599474\/pvaa004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T05:42:29Z","timestamp":1615786949000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/7\/2\/104\/5718009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,1,30]]},"published-print":{"date-parts":[[2021,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa004","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,1,30]]}}}